BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 24402660)

  • 1. [Clinical and histological findings in Fabry nephropathy].
    Pieruzzi F; Salerno F; Di Giacomo A; Torti G; Ferrario F; Pagni F; Stella A
    G Ital Nefrol; 2013; 30(6):. PubMed ID: 24402660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dialysis and transplantation in Fabry disease: indications for enzyme replacement therapy.
    Mignani R; Feriozzi S; Schaefer RM; Breunig F; Oliveira JP; Ruggenenti P; Sunder-Plassmann G
    Clin J Am Soc Nephrol; 2010 Feb; 5(2):379-85. PubMed ID: 20056752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzyme replacement therapy and Fabry nephropathy.
    Warnock DG; Daina E; Remuzzi G; West M
    Clin J Am Soc Nephrol; 2010 Feb; 5(2):371-8. PubMed ID: 20007680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers of Fabry disease nephropathy.
    Schiffmann R; Waldek S; Benigni A; Auray-Blais C
    Clin J Am Soc Nephrol; 2010 Feb; 5(2):360-4. PubMed ID: 19965549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Nephropathy in Fabry disease: possibilities for the radical improvement of prognosis for orphan diseases].
    Fomin VV; Pulin AA; Mukhin NA
    Ter Arkh; 2013; 85(6):4-9. PubMed ID: 23866592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Introduction to Focus on Fabry nephropathy: biomarkers, progression, and disease severity.
    Warnock DG; Remuzzi G; Brenner BM; Levin A; Wanner C
    Clin J Am Soc Nephrol; 2010 Feb; 5(2):359. PubMed ID: 20019119
    [No Abstract]   [Full Text] [Related]  

  • 7. [Renal involvement in Fabry's disease: diagnosis, follow-up and enzyme replacement therapy].
    Mignani R; Feriozzi S; Carraro G; Martinelli F; Cianciaruso B
    G Ital Nefrol; 2009; 26(5):577-84. PubMed ID: 19802803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The kidney in Fabry's disease.
    Pisani A; Visciano B; Imbriaco M; Di Nuzzi A; Mancini A; Marchetiello C; Riccio E
    Clin Genet; 2014 Oct; 86(4):301-9. PubMed ID: 24645664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac challenges in patients with Fabry disease.
    Weidemann F; Linhart A; Monserrat L; Strotmann J
    Int J Cardiol; 2010 May; 141(1):3-10. PubMed ID: 19720409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cystatin C as a marker of early changes of renal function in Fabry nephropathy.
    Feriozzi S; Germain DP; Di Vito R; Legrand A; Ricci R; Barbey F
    J Nephrol; 2007; 20(4):437-43. PubMed ID: 17879210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Department-related tasks and organ-targeted therapy in Fabry disease: an interdisciplinary challenge.
    Weidemann F; Sommer C; Duning T; Lanzl I; Möhrenschlager M; Naleschinski D; Arning K; Baron R; Niemann M; Breunig F; Schaefer R; Strotmann J; Wanner C
    Am J Med; 2010 Jul; 123(7):658.e1-658.e10. PubMed ID: 20609689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice.
    Terryn W; Cochat P; Froissart R; Ortiz A; Pirson Y; Poppe B; Serra A; Van Biesen W; Vanholder R; Wanner C
    Nephrol Dial Transplant; 2013 Mar; 28(3):505-17. PubMed ID: 23234755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fabry disease: molecular genetics of the inherited nephropathy.
    Desnick RJ; Astrin KH; Bishop DF
    Adv Nephrol Necker Hosp; 1989; 18():113-27. PubMed ID: 2564247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fabry disease: clinical spectrum and evidence-based enzyme replacement therapy.
    Desnick RJ; Banikazemi M
    Nephrol Ther; 2006 Jan; 2 Suppl 2():S172-85. PubMed ID: 17373219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Management of Fabry disease].
    Constantin T; Székely A; Ponyi A; Gulácsy V; Ambrus C; Kádár K; Vastagh I; Dajnoki A; Tóth B; Bokrétás G; Müller V; Katona M; Medvecz M; Fiedler O; Széchey R; Varga E; Rudas G; Kertész A; Molnár S; Kárpáti S; Nagy V; Magyar P; Mahdi M; Rákóczi E; Németh K; Bereczki D; Garami M; Erdos M; Maródi L; Fekete G
    Orv Hetil; 2010 Aug; 151(31):1243-51. PubMed ID: 20656661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Functional renal investigation in Fabry disease].
    Froissart M; Benistan K; Germain DP
    Presse Med; 2007 Mar; 36 Spec No 1():1S36-42. PubMed ID: 17546766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Rare renal diseases: diagnosis and nephrological mangement of Anderson-Fabry disease].
    Ranieri E
    G Ital Nefrol; 2009; 26(1):10. PubMed ID: 19255957
    [No Abstract]   [Full Text] [Related]  

  • 18. Cardiovascular testing in Fabry disease: exercise capacity reduction, chronotropic incompetence and improved anaerobic threshold after enzyme replacement.
    Lobo T; Morgan J; Bjorksten A; Nicholls K; Grigg L; Centra E; Becker G
    Intern Med J; 2008 Jun; 38(6):407-14. PubMed ID: 18613897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy.
    Breunig F; Wanner C
    J Nephrol; 2008; 21(1):32-7. PubMed ID: 18264934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Fabry disease--diagnostic guideline].
    Constantin T; Rákóczi E; Ponyi A; Ambrus C; Kádár K; Vastagh I; Dajnoki A; Tóth B; Bokrétás G; Müller V; Katona M; Csikós M; Fiedler O; Széchey R; Varga E; Rudas G; Kertész A; Molnár S; Kárpáti S; Nagy V; Magyar P; Mahdi M; Németh K; Bereczki D; Garami M; Erdos M; Maródi L; Fekete G;
    Orv Hetil; 2010 Feb; 151(7):243-9. PubMed ID: 20133243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.